Prince of Wales Hospital, Sir Y. K. Pao Cancer Center, Chinese University of Hong Kong, Peoples Republic of China
Received 20 December 2001; revised and accepted 8 February 2002
Abstract
Nasopharyngeal carcinoma (NPC) is endemic in southern China where genetic abnormalities and EpsteinBarr virus (EBV) infection are critical in the pathogenesis of the disease. Circulating EBV-DNA has been shown to improve prognostication and monitoring of NPC patients. Radiotherapy is the mainstay treatment for early disease and concurrent cisplatin/radiotherapy has been demonstrated to prolong survival in locoregionally advanced disease. Ongoing studies of targeting agents and immunotherapeutic approaches may further improve treatment results.
Key words: EpsteinBarr virus, nasopharyngeal carcinoma, review, treatment
Introduction
Nasopharyngeal carcinoma (NPC) occurs sporadically in the west but is endemic in southern China where it is the third most common form of malignancy amongst men, with incidence rates of between 15 and 50 per 100 000 [1]. There is an intermediate incidence in Alaskan Eskimos and in the Mediterranean basin.
The geographical pattern of incidence suggests a unique interaction of environmental and genetic factors. A stepwise progression of histological features that reflect underlying genetic events has recently been described. Patches of dysplasia are the earliest recognizable lesions, presumably in response to some environmental carcinogen. These are associated with allelic losses on the short arms of chromosomes 3 and 9 that result in inactivation of several tumor suppressor genes, particularly p14, p15 and p16 [25]. The relevant carcinogens have not been established but a link between the consumption of Chinese salted fish and other salted food items with the development of NPC has been suggested [1]. These dysplastic areas are the origin of the tumor but are probably insufficient in themselves to lead to further progression. At this stage latent EpsteinBarr virus (EBV) infection becomes critical and leads to the development of severe dysplasia. Gains of genes on chromosome 12 and allelic loss on 11q, 13q and 16q lead on to invasive carcinoma; metastasis is associated with mutation of p53 and aberrant expression of cadherins (Figure 1) [6, 7].
|
Presentation, imaging and staging
The most common presenting symptom is cervical lymphadenopathy, followed by nasal, aural and neurological symptoms. Only 5% of patients present with distant metastases in series from Southern China [12, 13]. Once the diagnosis is suspected on clinical grounds, histological confirmation of the diagnosis is mandatory. The technique of biopsy under local anesthesia has been found to have a diagnostic sensitivity comparable to that obtained by examination under general anesthesia. The biopsy is facilitated by direct visualization of the nasopharynx with a fiberoptic nasopharyngoscope. However, since the biopsy may cause soft tissue swelling and/or a hematoma, computed tomography (CT) scan and magnetic resonance imaging (MRI) of the nasopharynx and the skull base should be undertaken before the biopsy.
The primary tumor extent should be evaluated by both CT scan and MRI. The latter is more sensitive than CT scan for the detection of the primary tumor, its direct soft tissue extent, regional nodal metastasis and perineural extension. Blood vessels are clearly shown by MRI even without the use of intravenous contrast. On the other hand, although MRI can also demonstrate erosion into the base of the skull by virtue of the change in signal of fatty bone marrow, CT scan is generally considered a better tool for defining bone erosion. The role of positron emission tomography (PET) scanning in NPC remains to be defined, although preliminary reports indicate that it can be useful in detecting both local failures after treatment and distant metastases.
Prior to 1997, several different stage classifications were used but that described by Ho [1] was found to be superior to the others in its ability to predict prognosis and treatment outcome [12]. However, Hos classification was not ideal as an international system because it comprised five overall stages (instead of the usual practice of four), there were only three T-stages and it did not take into account CT scan evidence of tumor infiltration of the parapharyngeal region, a factor of considerable prognostic significance [13].
In 1997, therefore, a new UICC/AJCC stage classification was formulated, which incorporated all the major prognostically significant tumor parameters (Table 1). It is noteworthy that tumors infiltrating the parapharyngeal region were associated with a higher rate of both local failure and distant metastasis; such cases were classified as T2b (Table 1). The presence of orbital, infratemporal fossal and hypopharyngeal disease was grouped together with the presence of cranial nerve(s) palsy and intracranial tumor extension as T4. The poor prognosis of supraclavicular nodal metastases was recognized and classified as N3, together with very large nodes (>6 cm) (Table 1).
|
The demonstration that tumor-derived DNA is detectable in the plasma and serum of cancer patients raised the possibility that non-invasive detection and monitoring of NPC may be feasible. Using real-time quantitative PCR, cell-free EBV-DNA was found in the plasma of 96% of NPC patients and 7% of controls. Advanced-stage NPC patients had higher plasma EBV-DNA levels than tumors with early-stage disease [15]. Further studies have demonstrated that EBV-DNA may be a valuable tool for monitoring NPC patient response during radiotherapy and chemotherapy [16], as well as early detection of tumor recurrence [17]. In a cohort of 139 patients NPC patients treated with a uniform radiotherapy technique and followed up for a median period of 5.55 years, serum circulating EBV-DNA was found to be a significant prognosticator associated with NPC-related death in a Coxs regression analysis with a relative risk of 1.6 for each 10-fold increase in serum EBV-DNA concentration [18]. Thus the quantitation of EBV-DNA appears to allow improved prognostication of NPC. The sensitivity and specificity also suggests the potential use as a screening test in areas where NPC is endemic.
Radiotherapy
Up to the early 1990s, radical radiotherapy for NPC was delivered by two-dimensional (2D) techniques such as the one described by Ho [1]. The conventional practice had been to deliver tumoricidal radiation doses (total 6070 Gy; 22.5 Gy per fraction in a 67 week course) to anatomical structures at risk of tumor invasion in the vicinity of the nasopharynx by two lateral opposing fields or multiple fields. Appropriate shieldings were positioned at predetermined distances from bony landmarks [1] to protect vital neural organs. The neck was separately irradiated by another portal with avoidance of midline structures such as the spinal cord and the larynx [1]. With two-dimensional planning techniques, the local control rates for NPC were in the order of 80%, taking all T-stages together [13, 19]. In our experience, the overall survival (OS) figures after radiotherapy, using Hos technique, were 85% for Hos stages I and II and 55% for Hos stages III and IV (Figure 2) [13].
|
In general the clinical target volume (CTV) should include the whole GTV and the structures in the vicinity of the tumor, which are at substantial risk of subclinical infiltration. The sphenoid floor, the medial aspect of the greater wings of the sphenoid (and the foramin ovale, rotandum and lacerum), the vomer, the posterior choanae, the pterygoid plates, the pterygopalatine fossa, the posterior wall of the maxillary sinus, the parapharyngeal spaces bilaterally [21] and the prevertebral muscles and fascia are all at risk of tumor infiltration and should be included in the CTV. In T3 that infiltrates the clivus and T4 lesions, the entire clivus should be included in the CTV. However, in T1, T2 and less extensive T3 cases sparing the clivus, there has been no consensus on how much thickness of the clivus, if any at all, should be included in the CTV. Provided that the planning target volume (PTV) is not drawn too near to the brainstem (as described later), we recommend that the cortex of the clivus in juxtaposition to the tumor should be included in the CTV. In some T4 cases, the tumor has grossly infiltrated the inferior (or even the superior) orbital fissure and the whole bony orbit on that side should be included in the CTV. Intracranial extension via the foramen ovale when the tumor infiltrates laterally and superiorly through the pterygoid muscles is frequently associated with trigeminal nerve palsy. In such cases, the whole infratemporal fossal contents and the greater wing of sphenoid on the side of the lesion should be included in addition to the intracranial component of the cancer. Occasionally the tumor may infiltrate submucosally inferiorly to involve the oropharynx or even the hypopharynx. In these situations, the CTV has to be enlarged substantially in the inferior direction.
The PTV should, ideally, include the CTV with a safety margin that adequately caters for systemic and positional (set-up) errors (which can vary from center to center). Usually, a 5 mm safety margin should be adequate. However, the addition of safety margins in the posterosuperior direction on the CTV is hindered by the proximity of critical neural organs such as the brainstem, the spinal cord and the optic chiasma. To facilitate maximal dose sparing, we recommend that the PTV be drawn not closer to 5 mm of the critical neural organs. In the very advanced cases where the CTV is already within 5 mm for the critical neural organs, a phasic reduction in the PTV is required during the course of radiotherapy to avoid severe neurological sequelae.
Although the overall local control rate of NPC (all T-stages together) has been improved from 80% to 90% after using 3DCRT or IMRT, the major benefit is likely to be in the advanced T-stages (T3 and T4). The early T-stages were usually adequately irradiated with 2D-planning methods, with little chance of geographical misses [1, 19], even though conventional 2D-planning methods such as the Ho technique [1] have been shown to adequately circumscribe, at a high radiation dose, only GTV but not CTV or PTV (as described above) [20]. Indeed, when 2D external radiotherapy was supplemented by intracavitary brachytherapy, long-term local tumor control as high as 94% was reported for T1 and T2a [22]. For the more advanced T-stages, local failures occurred in one-third to two-thirds of cases after conventional 2D-planning methods [13, 19]. These patients should benefit most from 3DCRT or IMRT in terms of improvement in long-term local control by avoidance of geographical misses. On the other hand, the major benefit of 3DCRT/IMRT in the early T-stages should be reduction of severe late radiation complications such as chronic xerostomia, which detracts significantly from the quality of life of the long-term survivors of the disease.
Altered fractionation
In addition to improved radiotherapy techniques, use of altered fractionation and radiation dose escalation have been reported to improve the local control. Although a Radiation Therapy Oncology Group (RTOG) trial [23] has proved the superiority of both concomitant boost (accelerated hyperfractionated radiotherapy) and hyperfractionation over the conventional daily fractionation (2 Gy per fraction, five fractions per week) for head and neck cancers in general, the benefit for NPC has not been addressed specifically. Subgroup analysis for NPC was not possible in the RTOG trial due to the small numbers of NPC cases.
Recently, we have reported a significant increase in neurological complications, especially temporal lobe encephalopathy and cranial nerve(s) palsy, after a late-course bid hyper-/accelerated fractionated radiotherapy in a randomized comparison with conventional daily fractionation [24]. The temporal lobe and some other neurological complications arose despite keeping the interfraction time interval to 6 h. These observations have led us to conclude that the sublethal damage repair half-life of the central nervous tissue is likely to be longer than previously thought [24]. Clearly, the routine practice of a bid radiotherapy regimen together with a 2D-planning method should be avoided unless specific measures to avoid irradiation to neural organs are implemented [24]. This precaution is especially relevant to the advanced T-stage NPC, the tumor target of which is often in very close proximity to major neural organs such as the optic chiasma and the brainstem. On the other hand, improved local control by treating six fractions per week rather than five fractions per week has been recently reported [25]. By keeping most interfraction intervals to 24 h, the problem of inadequate sublethal damage repair of neurons of the bid technique can be avoided.
A definite relationship between total radiation dose and the local tumor control has been established in early T-stage NPC when the effect of dose escalation by intracavity brachytherapy after 6670 Gy of external beam radiation was studied [22]. However, brachytherapy is unable to deliver a significant dose to bulky parapharyngeal infiltration significant skull base involvements, or intracranial extensions, due to the geometrical dose fall-off with distance from the radioactive sources. Thus, the bulky T2b and the T3 and T4 cases benefit little from this approach. However, if the dosetumor response relationship above 6670 Gy demonstrated in early T-stage NPC is also applicable to the advanced T-stage, dose escalation above this level by means other than intraluminal brachytherapy should still be potentially beneficial in enhancing the local control of T3 and T4 disease. Studies using IMRT/3DCRT/stereotactic fractionated radiotherapy (SRT) to boost up the total dose of the advanced T-stage NPC may effectively and significantly improve the local control of ad-vanced T-stage NPC, but the final goal should be an increased therapeutic ratio when the trade off should not be an increase in radiation toxicities, especially chronic neural toxicities.
Combined modality treatment for locoregionally advanced disease
Although the initial remission rate is substantial with radiotherapy alone even in locoregionally advanced, UICC stages III and IV disease, the subsequent rates of both local and distant failures are high. Since NPC is highly chemosensitive, efforts have been made to incorporate chemotherapy into the primary treatment of the disease.
Following encouraging response rates to platinum-containing regimens in phase II studies in patients with metastatic disease, the use of neoadjuvant and adjuvant chemotherapy, combined with radiotherapy has been investigated in patients with locoregionally advanced disease in five prospective randomized trials (Table 2) [2630]. None of these trials demonstrated an improvement in OS. Although the International NPC Study Group trial showed a significant improvement in progression-free survival (PFS) [28], this was only achieved at the expense of an 8% treatment-related mortality. Hence, outside the context of a clinical study, the use of either neoadjuvant or adjuvant chemotherapy cannot be recommended as a standard therapeutic approach.
|
The Head and Neck Intergroup conducted a study comparing concurrent cisplatin and adjuvant cisplatin/5-fluorouracil (5-FU) with radiotherapy against radiotherapy alone in patients with stages III and IV NPC using the UICC 1987 classification [32]. The study was closed early after demonstrating significant OS and PFS advantage for the chemotherapy/radiotherapy group. Since the publication of this trial in 1998, the standard practice in North America has been concurrent chemotherapy/radiotherapy using cisplatin 100 mg/m2 3-weekly x3, followed by adjuvant cisplatin 80 mg/m2 on day 1 and 5-FU 1 g/m2 on days 14, 3-weekly x3. However, it is noteworthy that in this trial WHO type III histology (undifferentiated carcinoma) was present in only 44% of patients. In endemic areas such as southern China, the proportion of WHO type III histology will be >90%. Whether the results of a clinical trial derived from a heterogenous histological mix of patients can be directly applied to WHO type III undifferentiated NPC is not certain. Another factor that may have influenced the results of the trial was that the radiotherapy technique was not uniform among the participating Intergroup centers.
Furthermore, the benefit of concurrent chemotherapy during radiotherapy and adjuvant chemotherapy after radiotherapy cannot be separated in the Intergroup study. A randomized trial of 229 patients treated in the Institute Nazionale Tumori in Milan failed to demonstrate any survival benefit for patients receiving four cycles of vincristine, cyclophosphamide and doxorubicin compared with the patients receiving no adjuvant therapy [27]. In addition, the Meta-Analysis of Chemotherapy in Head and Neck Cancer collaborative group meta-analysis results of head and neck cancer in general have indicated no survival benefit of adjuvant chemotherapy [33]. These data suggest that most of the benefit of the Intergroup 0099 regimen was derived from concurrent chemotherapy/radiotherapy.
Based on the success of concurrent chemoradiation in head and neck cancers and the encouraging phase II data in NPC, we embarked on a study in locoregionally advanced NPC comparing radiotherapy with concurrent cisplatinradiotherapy. Patients with Hos N2 or N3 stage or N1 stage with nodal size 4 cm were eligible. Patients were randomized to receive cisplatin 40 mg/m2 on a weekly basis concurrently with external radiotherapy or radiotherapy alone. A total of 350 eligible patients were entered between April 1994 and November 1999. A preliminary PFS analysis demonstrated a trend towards benefit for the concurrent chemotherapy/radiotherapy arm [34]. Moreover, there was a very clear PFS benefit favoring chemotherapy/radiotherapy in the subgroup of Hos T3 (UICC T3/T4) patients with a hazards ratio of 2.49 (95% confidence interval 1.284.8). The benefit in the subgroup of advanced T stage patients was mainly attributable to a reduction in the rate of distant metastases. Based on the evidence of this latter study and Intergroup 0099 Study, the use of concurrent cisplatin/radiotherapy should become standard therapy for endemic locoregionally advanced T and N stage NPC patients.
Salvage of local failure after radiotherapy
Locoregional failures without distant metastases are potentially curable and should be treated aggressively. In the 1970s when the primary radiotherapy was often suboptimal in dose and tumor target coverage, the salvage rates of locally recurrent NPC by re-irradiation, mainly using external beams, were reported to be between 20 and 30% [35, 36]. However, as the primary radiotherapy improved, resulting in more adequate dose to the major part of the tumor, the rate of geographical misses lessened. The tumors that fail such treatment should, at least theoretically, be more radioresistant. Indeed, we reported little success of re-irradiation to a high dose using 2D-planned external beams for the salvage of local relapse [37]. Moreover, the complications of re-irradiation were many and severe. These included severe trismus that disrupted the patients speech and ability to eat and also radiation-induced temporal lobe encephalopathy and cranial nerve damage causing diplopia (VI) and dysphonia (VIIIXII) and even aspiration (VIIIXII ). In view of limited success but significant morbidity, we do not recommend 2D-planned external radiotherapy as a salvage for NPC local relapses [37].
In small (<5 cm in largest dimension) and suitably located recurrences that spare the nasal septum and the Eustachian cushions, over 60% long-term control was reported using 198Au implantation [38]. This interstitial brachytherapy delivered a very high dose to the local tumor but spared the important organs in the vicinity because of the inverse square law. However, it was associated with a not insignificant rate of troublesome headache and nasopharyngeal radiation necrosis that causes a foul smell and occasional epistaxis. In addition, palatal wound problems and even chronic non-healing palatal fistulas were also reported after 198Au implantation. The greatest drawback of this method is that it could only be applied to a minority of cases. Even though the procedure can be performed under endoscopic guidance, a split-palatal approach had been advocated for improved visualization and hemostasis [38]. Tumor infiltration of the parapharyngeal region is also a contraindication to 198Au implantation.
For tumors not amenable to 198Au implantation, in the absence of significant skull base erosion and intracranial extension or cranial nerve(s) palsy, surgical resection of the recurrent or persistent local tumor becomes the mainstay salvage treatment [39, 40]. There are various approaches to the nasopharyngectomy: transcervical, transoral and transpalatal, postero-lateral, transmaxillary (maxillary swing) [40] and midface deglove [41]. There is no ideal surgical approach that suits all cases of local relapses and there are advantages and disadvantages associated with each approach. The surgical procedure should therefore be tailored to the individual patient depending on the disease extent.
Treatment for distant metastases
The median survival for patients with distant metastases is around 9 months. Several chemotherapeutic agents have been used in the treatment of patients with locally recurrent and metastatic NPC. Older agents including methotrexate, bleomycin, 5-FU, cisplatin and carboplatin are the most active agents, with response rates varying from 15% to 31% [42]. Newer active agents include paclitaxel and gemcitabine with single agent response rates of 22 and 49%, respectively [43, 44]. Platinum-containing regimens have been used in phase II trials with encouraging response rates of 3880% (Table 3) [4550]. The response rates were clearly improved with more intensive chemotherapy. However, the question of whether the gain is sufficient to justify the added toxicities remains to be answered. Hence the current standard first-line therapy for metastatic NPC remains combination cisplatin and 5-FU.
|
Immunotherapy
There is evidence that HLA class I-restricted cytotoxic T-lymphocytes (CTL) play a major role in controlling EBV infections, and if CTL-mediated control is reduced e.g. in transplant patients receiving immunosuppressive treatment or in HIV-infected individuals, the cell growth-transforming ability of EBV is apparent, and life-threatening EBV-driven lymphoproliferative diseases may occur. Furthermore, these often regress following relaxation of immunosuppressive treatment and recovery of the cellular immune response. Hence there is considerable interest in the possibility of targeting this virus-specific immune response to treat human tumors that carry EBV. We have shown that functional CTLs are present in NPC tumor biopsies, and latent membrane protein (LMP) 2-specific CTL responses can be detected in untreated NPC patients [54]. Studies in NPC cell lines indicate that the tumor is capable of processing endogenously expressed EBV antigens for recognition by HLA class I-restricted CTL and this results in lysis of the malignant cell. There is hence a sound basis for treating NPC by boosting LMP2-specific CTL response. We are currently investigating several strategies that involve immunization with LMP2 peptide epitopes presented on autologous dendritic cells in metastatic NPC.
Footnotes
+ Correspondence to: Dr A. T. C. Chan, Department of Clinical Oncology, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, N.T. Hong Kong, Peoples Rebublic of China. Tel: +852-2632-2166; Fax: +852-2648-7097; E-mail: anthonytcchan@cuhk.edu.hk
References
1. Ho JHC. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978; 4: 183205.
2. Lo KW, Cheung ST, Leung SF et al. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 1996; 56: 27212725.[Abstract]
3. Chan AS, To KF, Lo KW et al. High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res 2000; 60: 53655370.
4. Lo KW, Teo PM, Hui AB et al. High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Res 2000; 60: 33483353.
5. Lo KW, Kwong J, Hui AB et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001; 61: 38773881.
6. Huang DP, Lo KW, van Hasselt CA et al. A region of homozygous deletion on chromosome 9p21-22 in primary nasopharyngeal carcinoma. Cancer Res 1994; 54: 40034006.[Abstract]
7. Hui AB, Lo KW, Leung SF et al. Detection of recurrent chromosomal and losses in primary nasopharyngeal carcinoma by comparative genomic hybridization. Int J Cancer 1999; 82: 498503.[ISI][Medline]
8. Shanmugaratnam K, Sobin LH. The World Health Organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition. Cancer 1993; 71: 26892697.[ISI][Medline]
9. Krueger GR, Wustrow J. Current histological classification of nasopharyngeal carcinoma at Cologne University. In Grundman (ed): Cancer Campaign; Nasopharyngeal Carcinoma, Vol. 5. Stuttgart: Gustay Fisher 1981; 1115.
10. Reddy SP, Raslan WF, Gooneratne S et al. Prognostic significance of keratinization in nasopharyngeal carcinoma. Am J Otolaryngol 1995; 16: 1038.
11. Marks JE, Phillips JL, Menck HR. The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 1998; 83: 582588.[ISI][Medline]
12. Teo PML, Leung SF, Yu P et al. A comparison of Hos, International Union Against Cancer, and American Joint Committee Stage Classifications for Nasopharyngeal Carcinoma. Cancer 1991; 67: 434439.[ISI][Medline]
13. Teo PML, Yu P, Lee WY et al. Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. Int J Radiat Oncol Biol Phys 1996; 36: 291304.[ISI][Medline]
14. OSullivan B, Chong V, Gospodarowicz MK et al. Nasopharyngeal carcinoma. In Gospodarowicz MK, Henson DE, Hutter RVP et al. (eds): Prognostic Factors in Cancer, 2nd edition. UICC TNM Project and Prognostic Factors Committee. New York, NY: John Wiley and Sons 2001.
15. Lo YMD, Chan LYS, Lo KW et al. Quantitative analysis of cell-free EpsteinBarr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59: 11881191.
16. Chan ATC, Lo YMD, Chan LYS et al. EBV DNA monitoring during chemotherapy for patients with undifferentiated nasopharyngeal carcinoma: a strong predictor of tumor response. Proc Am Soc Clin Oncol 2001; 20: (Abstr 928).
17. Lo YMD, Chan LYS, Chan ATC et al. Quantitative and temporal correlation between circulating cell-free EpsteinBarr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999; 59: 54525455.
18. Lo YMD, Chan ATC, Chan LYS et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating EpsteinBarr virus DNA. Cancer Res 2000; 60: 68786881.
19. Lee AWM, Poon YF, Foo W et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 19761985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992; 23: 261270.[ISI][Medline]
20. Xia P, Fu KK, Wong GW et al. Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2000; 48: 329337.[ISI][Medline]
21. Chau RMC, Teo PML, Choi PHK et al. Three-dimensional dosimetric evaluation of a conventional radiotherapy technique for treatment of nasopharyngeal carcinoma. Radiother Oncol 2001; 58: 143153.[ISI][Medline]
22. Teo PML, Leung SF, Lee WY, Zee B. Intracavitary brachytherapy significantly enhances local control of early T-stage nasopharyngeal carcinoma: the existence of a dosetumourcontrol relationship above conventional tumoricidal dose. Int J Radiat Oncol Biol Phys 2000; 46: 445458.[ISI][Medline]
23. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 716.[ISI][Medline]
24. Teo PML, Leung SF, Chan ATC et al. Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications. Int J Radiat Oncol Biol Phys 2000; 48: 13111322.[ISI][Medline]
25. Lee AWM, Sze WM, Yau TK et al. Retrospective analysis on treating nasopharyngeal carcinoma accelerated fractionation (6 fractions per week) in comparison conventional fractionation (5 fractions per week): report on control and normal tissue toxicity. Radiother Oncol 2001; 58: 121130.[ISI][Medline]
26. Chan ATC, Teo PML, Leung TWT et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995; 33: 569577.[ISI][Medline]
27. Rossi A, Molinari R, Boracchi P et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 1988; 6: 14011410.[Abstract]
28. International Nasopharynx Cancer Study Group. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy versus radiotherapy alone in stage IV ( N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys 1996; 35: 463469.[ISI][Medline]
29. Chua DTT, Sham JST, Choy D et al. Preliminary report of the AsianOceanian clinical oncology association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer 1998; 83: 22702283.[ISI][Medline]
30. Ma J, Mai HQ, Hong MH et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001; 19: 13501357.
31. Al-Sarraf M, Pajak TF, Cooper JS et al. Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a Radiation Therapy Oncology Group Study. J Clin Oncol 1990; 8: 13421351.[Abstract]
32. Al-Sarraf M, LeBlanc M, Giri PGS et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998; 16: 13101317.[Abstract]
33. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000; 355: 949955.
34. Chan AT, Teo PM, Ngan RK et al. A phase III randomized trial comparing concurrent chemotherapy/radiotherapy with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. Proc Am Soc Clin Oncol 2000; 19: (Abstr 1637).
35. Lee AWM, Law SCK, Foo W et al. Retrospective analysis of patients with nasopharyngeal carcinoma treated during 19761985: survival after local recurrence. Int Radiat Oncol Biol Phys 1993; 26: 773782.[ISI]
36. Wang CC. Re-irradiation of recurrent nasopharyngeal carcinoma: treatment techniques and results. Int J Radiat Oncol Biol Phys 1987; 13: 953956.[ISI][Medline]
37. Teo PML, Kwan WH, Chan ATC et al. How successful is high-dose (60 Gy) re-irradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma? Int J Radiat Oncol Biol Phys 1998; 40: 897913.[ISI][Medline]
38. Choy D, Sham JST, Wei WI et al. Transpalatal insertion of radioactive gold grain for the treatment of persistent and recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1993; 25: 505512.[ISI][Medline]
39. King WWK, Ku PKM, Mok CO, Teo PML. Nasopharyngectomy in the treatment of recurrent nasopharyngeal carcinoma: a twelve-year experience. Head Neck 2000; 22: 215222.[ISI][Medline]
40. Wei WI, Lam KH, Sham JST. New approach to nasopharynx: the maxillary swing approach. Head Neck 1991; 13: 200207.[ISI][Medline]
41. To EWH, Teo PML, Ku PKM, Pang PCW. Nasopharyngectomy for recurrent nasopharyngeal carcinoma: an innovative transnasal approach through a mid-face deglove incision with stereotactic navigation guidance. Br J Oral Maxillofacial Surg 2001; 39: 5562.[ISI][Medline]
42. Chan ATC, Teo PML, Leung WT, Johnson PJ. Role of chemotherapy in the management of nasopharyngeal carcinoma. Cancer 1998; 82: 10031012.[ISI][Medline]
43. Au E, Tan EH, Ang PT. Activity of paclitaxel by three-hour infusion in Asian patient with metastatic undifferentiated nasopharyngeal cancer. Ann Oncol 1998; 9: 327329.[Abstract]
44. Leong SS, Foo KF, Ang P et al. Phase II trial of gemcitabine in metastatic nasopharyngeal carcinoma. Lung Cancer 1999; 25: 242 (Abstr).
45. Yeo W, Leung TWT, Leung SF et al. Phase II study of combination carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. Cancer Chemoth Pharm 1996; 38: 466470.[ISI][Medline]
46. Yeo W, Leung TWT, Chan ATC et al. Phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer 1998; 34: 20272031.[ISI][Medline]
47. Tan EH, Khoo KS, Wee J et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 1999; 2: 235237.
48. Boussen H, Cvitkovic E, Wendling JL et al. Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin and fluorouracil. J Clin Oncol 1991; 9: 16751681.[Abstract]
49. Siu LL, Czaykowski PM, Tannock IF. Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx. J Clin Oncol 1998; 7: 25142521.
50. Ngan KC, Lau W, Yiu H et al. Combination gemcitabine and cisplatinum chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: an interim analysis of a phase II study. Proc Am Soc Clin Oncol 2001; 20: (Abstr 933).
51. Zheng X, Hu L, Chen F, Christensson B. Expression of Ki67 antigen, epidermal growth factor receptor and EpsteinBarr virus-encoded latent membrane protein (LMP1) in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol 1994; 30B: 290295.
52. Poon TCW, Chan ATC, To KF et al. Expression and prognostic significance of epidermal growth factor receptor and HER2 protein in nasopharyngeal carcinoma. Proc Am Soc Clin Oncol 2001; 20: (Abstr 913).
53. Hong WK, Arquette M, Nabell L et al. Efficacy and safety of the anti-epidermal growth factor antibody IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2001; 20: (Abstr 895).
54. Lee SP, Chan ATC, Cheung ST et al. Cytotoxic T lymphocyte control of EpsteinBarr virus in nasopharyngeal carcinoma (NPC): EBV-specific CTL response in the blood and tumour of NPC patients and the antigen processing function of the tumour cells. J Immunol 2000; 165: 573582.